Citations

Clear

9383 citation(s) found for "Thomas, PS".

Quality of Care in Non–Small-Cell Lung Cancer: Findings From 11 Oncology Practices in Florida
Corman, M., Lee, Ji‐Hyun , Fulp, William J. , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George P., Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Bepler, Gerold , Siegel, Erin M. , Shibata, David , Malafa, Mokenge P. , Jacobsen, Paul B. , Tanvetyanon, Tawee , Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | November 16, 2011 | Volume: 7 | Issue: 6 | Pages: e25-e31

10.1200/jop.2011.000228 | PMID 22379428 Get It

On the basis of this data set of participating institutions in Florida, several areas in the care of patients with non–small-cell lung cancer were identified as targets for future quality improvement efforts.
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
Hendrickson, Andrea E. Wahner , Yun, Seong Seok, Han, Jing, Schneider, Paula A., Koh, Brian D. , Stenson, Mary, Wellik, Linda, Shing, Jennifer C. , Peterson, Kevin L. , Flatten, Karen S., Hess, Allan D., Karp, Judith E. , Barr, Sharon, Gupta, Mamta , Smith, B. Douglas , Witzig, Thomas E. , Kaufmann, Scott H.

Mayo Clinic

Blood | November 12, 2011 | Volume: 119 | Issue: 2 | Pages: 476-487

10.1182/blood-2011-04-346601 | PMID 22080480 Get It

Abstract The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived. In the present study we compared the effects of rapamycin with the dual mTORC1/mTORC2 inhibitor OSI-027 in cell lines and clinical samples representing divers lymphoid malignancies. In contrast to rapamycin, OSI-027 markedly diminished proliferation and induced apoptosis in a variety of lymphoid cell lines and clinical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary syndrome. Additional analysis demonstrated that OSI-027–induced apoptosis depended on transcriptional activation of the PUMA and BIM genes. Overexpression of Bcl-2, which neutralizes Puma and Bim, or loss of procaspase 9 diminished OSI-027–induced apoptosis in vitro. Moreover, OSI-027 inhibited phosphorylation of mTORC1 and mTORC2 substrates, up-regulated Puma, and induced regressions in Jeko xenografts. Collectively, these results not only identify a pathway that is critical for the cytotoxicity of dual mTORC1/mTORC2 inhibitors, but also suggest that simultaneously targeting mTORC1 and mTORC2 might be an effective anti-lymphoma strategy in vivo.
LIM domain only 2 protein expression,LMO2germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era
Cerhan, James R. , Morton, Lindsay M. , Maurer, Matthew J. , Asmann, Yan W. , Vasef, Mohammad A., Lynch, Charles F. , Allmer, Cristine, Lossos, Izidore S. , Rothman, Nathaniel , Hartge, Patricia, Wang, Sophia , Natkunam, Yasodha , Habermann, Thomas M. , Cozen, Wendy , Slager, Susan L. , Chanock, Stephen Jacob , Doǧan, Ahmet , Maurer, Matthew , Cerhan, James R , Morton, Lindsay M , Wang, Sophia S

Mayo Clinic

Leukemia & Lymphoma | November 9, 2011 | Volume: 53 | Issue: 6 | Pages: 1105-1112

10.3109/10428194.2011.638717 | PMID 22066713 Get It

Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Perez, Edith A. , Davidson, Nancy E. , Visscher, Daniel W., Chen, Beiyun, Dakhil, Shaker R. , Zujewski, JoAnne, Moreno‐Aspitia, Alvaro , Pisansky, Thomas M. , Jenkins, Robert B. , Suman, Vera J. , Gralow, Julie R. , Kaufman, Peter A. , Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | November 1, 2011 | Volume: 29 | Issue: 34 | Pages: 4491-4497

10.1200/jco.2011.36.7045 | PMID 22042958 Get It

Purpose NCCTG (North Central Cancer Treatment Group) N9831 is the only randomized phase III trial evaluating trastuzumab added sequentially or used concurrently with chemotherapy in resected stages I to III invasive human epidermal growth factor receptor 2–positive breast cancer. Patients and Methods Patients received doxorubicin and cyclophosphamide every 3 weeks for four cycles, followed by paclitaxel weekly for 12 weeks (arm A), paclitaxel plus sequential trastuzumab weekly for 52 weeks (arm B), or paclitaxel plus concurrent trastuzumab for 12 weeks followed by trastuzumab for 40 weeks (arm C). The primary end point was disease-free survival (DFS). Results Comparison of arm A (n = 1,087) and arm B (n = 1,097), with 6-year median follow-up and 390 events, revealed 5-year DFS rates of 71.8% and 80.1%, respectively. DFS was significantly increased with trastuzumab added sequentially to paclitaxel (log-rank P < .001; arm B/arm A hazard ratio [HR], 0.69; 95% CI, 0.57 to 0.85). Comparison of arm B (n = 954) and arm C (n = 949), with 6-year median follow-up and 313 events, revealed 5-year DFS rates of 80.1% and 84.4%, respectively. There was an increase in DFS with concurrent trastuzumab and paclitaxel relative to sequential administration (arm C/arm B HR, 0.77; 99.9% CI, 0.53 to 1.11), but the P value (.02) did not cross the prespecified O'Brien-Fleming boundary (.00116) for the interim analysis. Conclusion DFS was significantly improved with 52 weeks of trastuzumab added to adjuvant chemotherapy. On the basis of a positive risk-benefit ratio, we recommend that trastuzumab be incorporated into a concurrent regimen with taxane chemotherapy as an important standard-of-care treatment alternative to a sequential regimen.
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Metzeler, Klaus H. , Becker, Heiko , Maharry, Kati , Radmacher, Michael D., Kohlschmidt, Jessica, Mrózek, Krzysztof , Whitman, Susan P., Wu, Yue-Zhong, Schwind, Sebastian , Powell, Bayard L., Carter, Thomas H. , Wetzler, Meir , Moore, Joseph O. , Kolitz, Jonathan E. , Baer, Maria R. , Carroll, Andrew J. , Larson, Richard A. , Marcucci, Guido , Bloomfield, Clara D. , Nicolet, Deedra , Caligiuri, Michael A. , Larson, Richard A

Mayo Clinic

Blood | October 27, 2011 | Volume: 118 | Issue: 26 | Pages: 6920-6929

10.1182/blood-2011-08-368225 | PMID 22031865 Get It

Abstract The associations of mutations in the enhancer of trithorax and polycomb family gene ASXL1 with pretreatment patient characteristics, outcomes, and gene-/microRNA-expression profiles in primary cytogenetically normal acute myeloid leukemia (CN-AML) are unknown. We analyzed 423 adult patients for ASXL1 mutations, other prognostic gene mutations, and gene-/microRNA-expression profiles. ASXL1 mutations were 5 times more common in older (≥ 60 years) patients (16.2%) than those younger than 60 years (3.2%; P < .001). Among older patients, ASXL1 mutations associated with wild-type NPM1 (P < .001), absence of FLT3-internal tandem duplications (P = .002), mutated CEBPA (P = .01), and with inferior complete remission (CR) rate (P = .04), disease-free survival (DFS; P = .03), overall survival (OS; P = .006), and event-free survival (EFS; P = .002). Within the European LeukemiaNet (ELN) genetic categories of older CN-AML, ASXL1 mutations associated with inferior CR rate (P = .02), OS (P < .001), and EFS (P < .001) among ELN Favorable, but not among ELN Intermediate-I patients. Multivariable analyses confirmed associations of ASXL1 mutations with unfavorable CR rate (P = .03), DFS (P < .001), OS (P < .001), and EFS (P < .001) among ELN Favorable patients. We identified an ASXL1 mutation-associated gene-expression signature, but no microRNA-expression signature. This first study of ASXL1 mutations in primary CN-AML demonstrates that ASXL1mutated older patients, particularly within the ELN Favorable group, have unfavorable outcomes and may be candidates for experimental treatment approaches.
Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women
Limsui, David, Vierkant, Robert A. , Tillmans, Lori S. , Wang, Alice H., Weisenberger, Daniel J. , Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Cerhan, James R. , Laird, Peter W. , Slager, Susan L. , Limburg, Paul J. , Cerhan, James R , Vierkant, Robert A , Haile, Robert W , Potter, John D

Mayo Clinic

Gut | October 25, 2011 | Volume: 61 | Issue: 9 | Pages: 1299-1305

10.1136/gutjnl-2011-300719 | PMID 22027477 Get It

Background Postmenopausal hormone (PMH) therapy may reduce colorectal cancer (CRC) risk, but existing data are inconclusive. Objectives To evaluate associations between PMH therapy and incident CRC, overall and by molecularly defined subtypes, in the population-based Iowa Women's Health Study of older women. Methods Exposure data were collected from Iowa Women's Health Study participants (55–69 years) at baseline (1986). Archived, paraffin-embedded tissue specimens for 553 CRC cases were collected and analysed to determine microsatellite instability (MSI-L/MSS or MSI-H), CpG island methylator phenotype (CIMP-negative or CIMP-positive) and BRAF mutation ( BRAF -wildtype or BRAF -mutated) status. Multivariable Cox regression models were fit to estimate RRs and 95% CIs. Results PMH therapy (ever vs never use) was inversely associated with incident CRC overall (RR=0.82; 95% CI 0.72 to 0.93), with a significantly lower risk for MSI-L/MSS tumours (RR=0.75; 95% CI 0.60 to 0.94), and borderline significantly lower risks for CIMP-negative (RR=0.79; 95% CI 0.63 to 1.01) and BRAF -wildtype (RR=0.83; 95% CI 0.66 to 1.04) tumours. For PMH therapy >5 years, the subtype-specific risk estimates for MSI-L/MSS, CIMP-negative and BRAF -wildtype tumours were: RR=0.60, 95% CI 0.40 to 0.91; RR=0.68, 95% CI 0.45 to 1.03; and RR=0.70, 95% CI 0.47 to 1.05, respectively. PMH therapy was not significantly associated with the MSI-H, CIMP-positive or BRAF -mutated CRC subtypes. Conclusions In this prospective cohort study, PMH therapy was inversely associated with distinct molecularly defined CRC subtypes, which may be related to differential effects from oestrogen and/or progestin on heterogeneous pathways of colorectal carcinogenesis.
The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor–Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists
Joh, Jennifer E., Esposito, Nicole N., Laronga, Christine , Lee, M. Catherine, Loftus, Loretta , Reynolds, Carol, Lawton, Thomas J. , Ács, Péter, Gordan, Lucio , Ács, Géza, Kiluk, John V. , Soliman, Hatem Hussein , Boughey, Judy C.

Mayo Clinic

The Oncologist | October 21, 2011 | Volume: 16 | Issue: 11 | Pages: 1520-1526

10.1634/theoncologist.2011-0045 | PMID 22016474 Get It

Abstract Purpose. The Oncotype DX assay predicts likelihood of distant recurrence and improves patient selection for adjuvant chemotherapy in estrogen receptor–positive (ER-positive) early stage breast cancer. This study has two primary endpoints: to evaluate the impact of Oncotype DX recurrence scores (RS) on chemotherapy recommendations and to compare the estimated recurrence risk predicted by breast oncology specialists to RS. Methods. One hundred fifty-four patients with ER-positive early stage breast cancer and available RS results were selected. Clinicopathologic data were provided to four surgeons, four medical oncologists, and four pathologists. Participants were asked to estimate recurrence risk category and offer their chemotherapy recommendations initially without and later with knowledge of RS results. The three most important clinicopathologic features guiding their recommendations were requested. Results. Ninety-five (61.7%), 45 (29.2%), and 14 (9.1%) tumors were low, intermediate, and high risk by RS, respectively. RS significantly correlated with tumor grade, mitotic activity, lymphovascular invasion, hormone receptor, and HER2/neu status. Estimated recurrence risk by participants agreed with RS in 54.2% ± 2.3% of cases. Without and with knowledge of RS, 82.3% ± 1.3% and 69.0% ± 6.9% of patients may be overtreated, respectively (p = 0.0322). Inclusion of RS data resulted in a 24.9% change in treatment recommendations. There was no significant difference in recommendations between groups of participants. Conclusions. Breast oncology specialists tended to overestimate the risk of tumor recurrence compared with RS. RS provides useful information that improves patient selection for chemotherapy and changes treatment recommendations in approximately 25% of cases.
Role of Substance P in the Regulation of Glucose Metabolism via Insulin Signaling-Associated Pathways
Καραγιαννίδης, Ιορδάνης, Bakirtzi, Kyriaki , Kokkotou, Efi, Stavrakis, Dimitris, Thomou, Thomas , Giorgadze, Nino, Kirkland, James L. , Pothoulakis, Charalabos , Margolis, Kara Gross

Mayo Clinic

Endocrinology | October 19, 2011 | Volume: 152 | Issue: 12 | Pages: 4571-4580

10.1210/en.2011-1170 | PMID 22009727 Get It

Substance P (SP), encoded by the tachykinin 1 (Tac1) gene, is the most potent tachykinin ligand for the high-affinity neurokinin-1 receptor (NK-1R). We previously reported that NK-1R-deficient mice show less weight gain and reduced circulating levels of leptin and insulin in response to a high-fat diet (HFD) and demonstrated the presence of functional NK-1R in isolated human preadipocytes. Here we assessed the effects of SP on weight gain in response to HFD and determined glucose metabolism in Tac1-deficient (Tac1−/−) mice. The effect of SP on the expression of molecules that may predispose to reduced glucose uptake was also determined in isolated human mesenteric, omental, and sc preadipocytes. We show that although weight accumulation in response to HFD was similar between Tac1−/− mice and wild-type littermates, Tac1−/− mice demonstrated lower glucose and leptin and increased adiponectin blood levels and showed improved responses to insulin challenge after HFD. SP stimulated phosphorylation of c-Jun N-terminal kinase, protein kinase Cθ, mammalian target of rapamycin, and inhibitory serine insulin receptor substrate-1 phosphorylation in human preadipocytes in vitro. Preincubation of human mesenteric preadipocytes with the protein kinase Cθ pseudosubstrate inhibitor reduced insulin receptor substrate 1 phosphorylation in response to SP. Lastly, SP also induced insulin receptor substrate-1 phosphorylation in mature human sc adipocytes. Our results demonstrate an important role for SP in adipose tissue responses and obesity-associated pathologies. These novel SP effects on molecules that enhance insulin resistance at the adipocyte level may reflect an important role for this peptide in the pathophysiology of type 2 diabetes.
miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival
Park, Jong Kook , Kogure, Takayuki , Nuovo, Gerard J., Jiang, Jinmai , He, Lei , Kim, Ji Hye , Phelps, Mitch A. , Papenfuss, Tracey L. , Schmittgen, Thomas D. , Croce, Carlo Maria , Patel, Tushar , Phelps, Mitch

Mayo Clinic

Cancer Research | October 18, 2011 | Volume: 71 | Issue: 24 | Pages: 7608-7616

10.1158/0008-5472.can-11-1144 | PMID 22009537 Get It

Abstract Patients with advanced hepatocellular carcinoma (HCC) face a dismal prognosis because of a lack of any effective therapies. To address this situation, we conducted a preclinical investigation of the therapeutic efficacy of oligonucleotides directed against the oncogenic microRNA miR-221, which has been implicated in HCC. Of 9 chemistries evaluated, we determined that a 2′-O-methyl phosphorothioate-modified anti-miR-221 oligonucleotide was most effective at reducing proliferation in vitro. A cholesterol-modified isoform of anti-miR-221 (chol-anti-miR-221) exhibited improved pharmacokinetics and liver tissue distribution compared with unmodified oligonucleotide. Chol-anti-miR-221 significantly reduced miR-221 levels in liver within a week of intravenous administration and in situ hybridization studies confirmed accumulation of the oligonucleotide in tumor cells in vivo. Within the same period, chol-anti-miR-221 reduced tumor cell proliferation and increased markers of apoptosis and cell-cycle arrest, elevating the tumor doubling time and increasing mouse survival. Taken together, our findings offer a preclinical proof of efficacy for chol-anti-miR-221 in a valid orthotopic mouse model of HCC, suggesting that this targeted agent could benefit treatment for patients with advanced HCC. Cancer Res; 71(24); 7608–16. ©2011 AACR.
Biomarkers of Left Ventricular Hypertrophy and Remodeling in Blacks
Coutinho, Thais , Al-Omari, Malik A., Mosley, Thomas H. , Kullo, Iftikhar J.

Mayo Clinic

Hypertension | October 11, 2011 | Volume: 58 | Issue: 5 | Pages: 920-925

10.1161/hypertensionaha.111.178095 | PMID 21986506 Get It

Left ventricular (LV) hypertrophy, a marker for adverse cardiovascular events, is more common in blacks than in non-Hispanic whites. Mechanisms leading to LV hypertrophy and mediating its clinical sequelae in blacks are not fully understood. We investigated the associations of 39 candidate biomarkers in distinct biological pathways with LV mass and geometry in blacks. Participants included 1193 blacks (63±9 years of age; 72% women; 78% hypertensive) belonging to hypertensive sibships. LV mass was measured by transthoracic echocardiography and indexed to height. 2.7 LV geometry was categorized as normal, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy. Generalized estimating equations were used to assess associations of the 39 biomarkers with LV mass index after adjustment for age, sex, and conventional risk factors. After adjustment for potential confounders, log-transformed levels of the following biomarkers were independently associated with LV mass index: N-terminal pro-brain natriuretic peptide (β±SE=0.07±0.01 pg/mL; P <0.0001), mid-regional pro-atrial natriuretic peptide (β±SE=0.08±0.02 pmol/L; P <0.0001), mid-regional pro-adrenomedullin (β±SE=0.09±0.03 nmol/L; P =0.0006), C-terminal pro-endothelin (β± SE=0.05±0.02 pmol/L; P =0.0009), and osteoprotegerin (β±SE=0.07±0.02 pg/mL; P =0.0005) (β is for 1 log increase in biomarker level). The associations of these biomarkers with LV mass index were mainly due to their association with eccentric hypertrophy. Higher circulating levels of natriuretic peptides, adrenomedullin, endothelin, and osteoprotegerin were associated with increased LV mass index, providing insights into the pathophysiology of LV hypertrophy in blacks.